Linike Medical Group Ltd
Linike Medical Group Ltd. engages in the renewable energy business. The company is involved in the creation of a solar farm in India. It also focuses on commercial real estate development business. The company was formerly known as Litian Group Inc. and changed its name to Linike Medical Group Ltd. in August 2021. Linike Medical Group Ltd. is based in Calgary, Canada.
Linike Medical Group Ltd (LNMG) - Net Assets
Latest net assets as of January 2025: $37.26 Million USD
Based on the latest financial reports, Linike Medical Group Ltd (LNMG) has net assets worth $37.26 Million USD as of January 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($57.68 Million) and total liabilities ($20.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $37.26 Million |
| % of Total Assets | 64.6% |
| Annual Growth Rate | 97.77% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2516.27 |
Linike Medical Group Ltd - Net Assets Trend (2012–2024)
This chart illustrates how Linike Medical Group Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Linike Medical Group Ltd (2012–2024)
The table below shows the annual net assets of Linike Medical Group Ltd from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-10-31 | $34.90 Million | -0.70% |
| 2023-10-31 | $35.14 Million | +46789.69% |
| 2022-10-31 | $-75.27K | -56.38% |
| 2021-10-31 | $-48.13K | -163.44% |
| 2020-10-31 | $-18.27K | +96.20% |
| 2013-10-31 | $-480.74K | -5033.24% |
| 2012-10-31 | $9.74K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Linike Medical Group Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 64856800.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (October 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $540.33K | 1.55% |
| Common Stock | $66.89K | 0.19% |
| Other Components | $34.29 Million | 98.26% |
| Total Equity | $34.90 Million | 100.00% |
Linike Medical Group Ltd Competitors by Market Cap
The table below lists competitors of Linike Medical Group Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
European Resources Limited
AU:ERE
|
$108.53 |
|
MALAWI PROPERTY INVESTMENT COMPANY
MSE:MPICO
|
$108.81 |
|
Golden Prospect Precious Metals Ltd
LSE:GPM
|
$109.21 |
|
BRAZILIAN METAL
BE:LR4
|
$109.36 |
|
QUIZ PLC
LSE:QUIZ
|
$108.07 |
|
PLATSEARCH
BE:P2T
|
$108.03 |
|
Pembroke VCT PLC
LSE:PEMB
|
$107.75 |
|
Digital Media Solutions Inc.
OTCQB:DMSL
|
$107.62 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Linike Medical Group Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 35,143,331 to 34,898,451, a change of -244,880 (-0.7%).
- Net loss of 244,879 reduced equity.
- Other comprehensive income decreased equity by 34,358,126.
- Other factors increased equity by 34,358,125.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-244.88K | -0.7% |
| Other Comprehensive Income | $-34.36 Million | -98.45% |
| Other Changes | $34.36 Million | +98.45% |
| Total Change | $- | -0.70% |
Book Value vs Market Value Analysis
This analysis compares Linike Medical Group Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.21x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 310.18x to 0.21x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-10-31 | $0.00 | $0.01 | x |
| 2013-10-31 | $-0.23 | $0.01 | x |
| 2020-10-31 | $0.00 | $0.01 | x |
| 2021-10-31 | $0.00 | $0.01 | x |
| 2022-10-31 | $0.00 | $0.01 | x |
| 2023-10-31 | $0.05 | $0.01 | x |
| 2024-10-31 | $0.05 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Linike Medical Group Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.88%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.59x
- Recent ROE (-0.70%) is above the historical average (-129.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -906.65% | -127.49% | 2.10x | 3.39x | $-89.33K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-379.69K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-86.74K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.05K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-58.45K |
| 2023 | 2.82% | 11.07% | 0.16x | 1.56x | $-2.52 Million |
| 2024 | -0.70% | -1.88% | 0.23x | 1.59x | $-3.73 Million |
Industry Comparison
This section compares Linike Medical Group Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Linike Medical Group Ltd (LNMG) | $37.26 Million | -906.65% | 0.55x | $108.24 |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |